^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    itacitinib (INCB039110)

    i
    Other names: INCB039110, INCB-039110, INCB 39110, INCB39110, INCB-39110, INCB 039110, IBI-377, IBI377, IBI 377
    Company:
    Incyte, Innovent Biologics
    Drug class:
    JAK1 inhibitor
    Related drugs:
    25d
    Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=8, Terminated, M.D. Anderson Cancer Center | Trial completion date: May 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2027 --> Oct 2025; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    itacitinib (INCB039110)
    2ms
    Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Phase classification: P1 --> P2
    Phase classification
    |
    cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)
    2ms
    Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110)
    3ms
    Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • itacitinib (INCB039110)
    4ms
    Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov)
    P2, N=27, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: Jun 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    JAK1 (Janus Kinase 1) • CRP (C-reactive protein)
    |
    Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)
    6ms
    A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. (PubMed, Leuk Res)
    Overall, 8 of 23 patients enrolled achieved SVR at week 24; larger average changes in SVR at week 12 were observed for itacitinib monotherapy vs. the combination. No unexpected safety signals were observed.
    P2 data • Journal
    |
    JAK1 (Janus Kinase 1)
    |
    Jakafi (ruxolitinib) • itacitinib (INCB039110)
    6ms
    Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110) • dezapelisib (INCB040093)
    6ms
    NCI-2022-03765: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=50 --> 20
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • itacitinib (INCB039110)
    8ms
    Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)
    9ms
    Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jan 2026
    Trial completion date
    |
    sirolimus • melphalan • fludarabine IV • itacitinib (INCB039110)
    10ms
    Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Jan 2025 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110) • dezapelisib (INCB040093)
    12ms
    Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov)
    P2, N=27, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    JAK1 (Janus Kinase 1) • CRP (C-reactive protein)
    |
    Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)